Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 100; no. 11; pp. e446 - e449
Main Authors Kastritis, Efstathios, Kyrtsonis, Marie-Christine, Morel, Pierre, Gavriatopoulou, Maria, Hatjiharissi, Evdoxia, Symeonidis, Argirios S, Vassou, Amalia, Repousis, Panagiotis, Delimpasi, Sossana, Sioni, Anastasia, Michalis, Evrydiki, Michael, Michail, Vervessou, Elina, Voulgarelis, Michael, Tsatalas, Costantinos, Terpos, Evangelos, Dimopoulos, Meletios A
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.11.2015
Subjects
Aged
Aged, 80 and over
Disease-Free Survival
Female
Follow-Up Studies
Humans
Male
Middle Aged
Models, Biological
Online Only
Risk Factors
Rituximab - administration & dosage
Rituximab - adverse effects
Survival Rate
Waldenstrom Macroglobulinemia - drug therapy
Waldenstrom Macroglobulinemia - mortality
Rituximab
fludarabine
cyclophosphamide
prognosis
age
lymphoma
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2015.124149